NVO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	8.10M
Vidutinė apimtis	4.84M
Rinkos kapitalizacija	548.10B
EPS	$0 ( 2024-01-31 )
Last Dividend	$0.884 ( 2023-08-18 )
Next Dividend	$0 ( N/A )
P/E	46.45
ATR14	$0.114 (0.09%)

Tūris Koreliacija

Ilgas: -0.88 (strong negative)

Trumpas: 0.58 (weak)

Signal:(30.746) Neutral

Novo Nordisk A/S Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Novo Nordisk A/S Koreliacija - Valiuta/Žaliavos

0.85
( strong )

0.83
( strong )

0.00
( neutral )

0.83
( strong )

-0.84
( strong negative )

-0.76
( moderate negative )

Novo Nordisk A/S Finansinės ataskaitos

Annual	2023
Pajamos:	$232.26B
Bruto pelnas:	$196.50B (84.60 %)
EPS:	$18.67

FY	2023
Pajamos:	$232.26B
Bruto pelnas:	$196.50B (84.60 %)
EPS:	$18.67

FY	2022
Pajamos:	$176.95B
Bruto pelnas:	$148.51B (83.92 %)
EPS:	$12.26

FY	2021
Pajamos:	$140.80B
Bruto pelnas:	$117.14B (83.20 %)
EPS:	$20.46

Financial Reports:

No articles found.

Novo Nordisk A/S Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.584 (N/A)	$0 (N/A)	$1.189 (N/A)	$0 (N/A)	$0.884 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Novo Nordisk A/S Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.78 - good (77.78%) | Divividend Growth Potential Score: 4.56 - Stable (8.80%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.000600	1982-04-23
Last Dividend	$0.884	2023-08-18
Next Dividend	$0	N/A
Payout Date	2023-08-29
Next Payout Date	N/A
# dividends	53	--
Total Paid Out	$15.84	--
Avg. Dividend % Per Year	2.26%	--
Score	4.29	--
Div. Sustainability Score	7.78
Div.Growth Potential Score	4.56
Div. Directional Score	6.17	--

Next Divdend (Est)
(2024-05-27)

$0.906 Estimate 6.52 %

Dividend Stability

0.26 Very Poor

Dividend Score

4.29

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
1982	$0.000600	0.30%
1983	$0.00274	1.29%
1984	$0.00288	1.02%
1985	$0.00259	2.18%
1986	$0.00344	2.37%
1987	$0.00414	2.50%
1988	$0.00522	4.51%
1989	$0.00463	2.39%
1990	$0.00624	2.51%
1991	$0.00509	1.64%
1992	$0.00600	1.32%
1993	$0.00540	1.22%
1994	$0.0112	2.26%
1995	$0.00840	1.80%
1996	$0.0158	2.26%
1997	$0.0112	1.24%
1998	$0.0161	1.13%
1999	$0.0164	1.17%
2000	$0.0422	3.13%
2001	$0.0318	1.79%
2002	$0.0369	1.84%
2003	$0.0523	3.56%
2004	$0.0745	3.62%
2005	$0.0840	3.17%
2006	$0.0966	3.39%
2007	$0.122	2.93%
2008	$0.177	2.77%
2009	$0.207	3.92%
2010	$0.281	4.28%
2011	$0.364	3.27%
2012	$0.499	4.26%
2013	$0.637	3.84%
2014	$0.830	4.52%
2015	$0.760	3.58%
2016	$1.411	4.92%
2017	$1.137	6.33%
2018	$1.137	4.20%
2019	$1.238	5.29%
2020	$1.301	4.46%
2021	$1.506	4.22%
2022	$1.620	2.98%
2023	$2.07	3.03%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.360	1.500	2.79	4.19	[0 - 0.5]
returnOnAssetsTTM	0.266	1.200	1.130	1.356	[0 - 0.3]
returnOnEquityTTM	0.905	1.500	1.056	1.585	[0.1 - 1]
payoutRatioTTM	0.380	-1.000	6.20	-6.20	[0 - 1]
currentRatioTTM	0.823	0.800	-0.884	-0.708	[1 - 3]
quickRatioTTM	0.622	0.800	-1.048	-0.839	[0.8 - 2.5]
cashRatioTTM	0.0848	1.500	-0.640	-0.960	[0.2 - 2]
debtRatioTTM	0.0859	-1.500	8.57	-10.00	[0 - 0.6]
interestCoverageTTM	69.78	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	24.39	2.00	1.869	3.74	[0 - 30]
freeCashFlowPerShareTTM	15.68	2.00	2.16	4.32	[0 - 20]
debtEquityRatioTTM	0.253	-1.500	8.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.846	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.442	1.000	3.17	3.17	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.03	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.739	0.800	8.41	6.73	[0.5 - 2]
Total Score				7.78

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	47.98	1.000	5.26	0	[1 - 100]
returnOnEquityTTM	0.905	2.50	4.25	1.585	[0.1 - 1.5]
freeCashFlowPerShareTTM	15.68	2.00	4.77	4.32	[0 - 30]
dividendYielPercentageTTM	0.113	1.500	7.17	0	[0 - 0.4]
operatingCashFlowPerShareTTM	24.39	2.00	1.869	3.74	[0 - 30]
payoutRatioTTM	0.380	1.500	6.20	-6.20	[0 - 1]
pegRatioTTM	0.198	1.500	-2.01	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.469	1.000	0.777	0	[0.1 - 0.5]
Total Score				4.56

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.